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Abstract 
Objective Recent studies have proved that blockade of the renin-angiotensin 
system (RAS) retards the progression of diabetic nephropathy, whereas 
hyporeninemia is known as a typical state in diabetic subjects. The purpose of 
this study is to determine whether expression levels of RAS differ between non-
diabetic and diabetic renal tissues with accurate quantitative method.  
Research Design and Methods Subjects were 66 non-diabetic and 8 diabetic 
patients with biopsy-proven renal diseases. The 8 diabetic subjects suffered from 
type 2 diabetes mellitus with overt proteinuria. Renal histology revealed typical 
diffuse or nodular lesions with linear IgG deposit on immuno-fluorescent 
staining and thickened basement membrane on electronic microscopy. Total 
RNA from a small part of the renal cortical biopsy specimens was reverse-
transcribed and the resultant cDNA was amplified for new major components of 
RAS, i.e., renin, renin receptor, angiotensinogen, angiotensin converting enzyme, 
angiotensin converting enzyme 2, angiotensin II type 1 receptor, angiotensin II 
type 2 receptor and measured.  
Results Among these components, a significant up-regulation was observed in 
angiotensin converting enzyme gene in diabetic renal tissue.  
Conclusion The results suggest that renal tissue RAS might be activated in the 
respect that ACE gene expression is up-regulated in spite of a tendency to low 
renin expression in type 2 diabetic nephropathy.  
 
 -2-  
  
Key words: Angiotensin-Converting Enzyme, ACE, Angiotensinogen, Renin-
Angiotensin-Aldosterone System, RAAS , Nephropathy 
 
 
 -3-  
  
 Recently proposed mechanisms for the development of diabetic 
nephropathy (DN) include glomerular hyperfiltration (1), disorientation of 
intracellular signal transduction (2) and involvement of advanced glycation 
endproducts (3). Activation of the renin-angiotensin system (RAS) by high 
glucose, mechanical stress and proteinuria has been implicated in the major 
changes associated with diabetic nephropathy (4). Thus, renal tissue activation of 
RAS is thought to contribute to deterioration in renal function of DN. Recently a 
number of large-scale prospective studies have proven that blockade of the 
system with angiotensin converting enzyme (ACEI) and angiotensin II receptor 
blocker (ARB) retards the progression of DN (5-11). Actually, several studies 
suggest that the RAS is activated especially at the early stage (12; 13). However, 
from early studies, hyporeninemia has been well known as a typical state of 
circulatory RAS in diabetic subjects at the late stage (14; 15), . Although the 
tissue RAS is thought to be controlled independently of the circulatory RAS, this 
apparent paradox is still difficult to interpret. It is supposed that the tissue RAS 
is activated in contrast to the circulatory RAS and several non- or semi-
quantitative evaluations were made. However, direct or quantitative evidence in 
human diabetic nephropathy is very scarce so far. Furthermore, new major 
components for RAS, renin receptor (RER) (16) and angiotensin converting 
enzyme 2 (ACE2) (17) have emerged recently.  
 The purpose of this study is to determine whether expression levels of RAS 
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including RER and ACE2 differ between non-diabetic and diabetic human renal 
tissues with full quantitative evaluation. For this sake, real time PCR with a very 
small part of renal biopsy specimen was applied, making an accurate 
quantification of mRNA possible, in spite of the inability in similar protein 
evaluation because of the limitation of specimens’ quantity.  
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Materials and Methods  
 Subjects were 66 non-diabetic and 8 diabetic patients with biopsy-proven 
renal diseases. The study was approved at the ethic committee of Fukui 
University (No.17-12) and consent was obtained from all individuals for 
inclusion onto the study. Salt-intake was standardized to 10 g daily in 
hospitalization. The non-diabetic patients consisted of 8 with minor 
abnormalities, 8 benign nephrosclerosis, 38 primary glomerulonephritis 
including 4 minimal change nephrotic syndrome and 12 lupus nephritis. Major 
clinical characteristics were listed in table 1. Significant difference was observed 
in age, systolic blood pressure (SBP) and serum creatinine concentration (s-Cr) 
between 2 groups. The total patients’ number of administered depressors at renal 
biopsy were as follows: calcium channel blocker (CCB); 5 in non-diabetics and 
4 in diabetics, α-blocker; 0 in non-diabetics and 1 in diabetics, diuretics; 8 in 
non-diabetics and 1 in diabetics, ACEI; 1 in non-diabetics and 0 in diabetics, 
ARB; 0 in non-diabetics and 0 in diabetics. Administered ACEI and ARB were 
replaced by CCB or α-blocker prior to biopsy. Creatinine clearance (Ccr) was 
determined with s-Cr and urinary creatinine concentration (u-Cr) and ml of daily 
urine volumes (UV) by a standard formula, Ccr = u-Cr x UV/s-Cr/1440 
(ml/min.). Plasma renin activity (PRA) of diabetic patients tended to be lower 
than that of the non diabetic subjects (p=0.11). The diabetic patients consisted of 
6 males and 2 females suffering from type 2 diabetes mellitus with proteinuria, 
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aged from 32 to 74 years. Three of them were treated with oral administration of 
glibenclamide and 3 other patients were treated with insulin injection. 
Glycosylated hemoglobin ranged from 4.0 to 8.7% at renal biopsy. Renal 
histology revealed typical diffuse or nodular lesions with linear IgG deposit on 
immuno-fluorescent staining and thickened basement membrane on electronic 
microscopy (table 2).  
 Renal RNA was extracted from a small part of the renal cortex of the 
subjects (about 2 mm) by echographic-guided percutaneous renal biopsy with 
18G needle. Each specimen corresponds to a size and site presumed to contain 
about 20-30 glomeruli. Immediately after obtaining the biopsy specimen, total 
RNA was extracted using RNA-Bee (TEL-TEST, INC., USA) according to the 
protocol recommended by the manufacturer. Single strand cDNA was 
synthesized by a reverse transcriptase reaction with 500 ng/µl Oligo-dT 
(TOYOBO Inc., Japan) and M-MLV reverse transcriptase (TOYOBO CO. LTD., 
Japan). The resultant cDNA was amplified for renin (REN), RER, 
angiotensinogen (AGT), angiotensin converting enzyme (ACE), ACE2, 
angiotensin II type 1 receptor (AT1), angiotensin II type 2 receptor (AT2) as 
target genes and GAPDH as a house-keeping gene. The sequences for primers 
were as follows; REN: 5’-GTGTCTGTGGGGTCATCCACCTTG-3’ (sense) 
and 5’-GGATTCCTGAAATACATAGTCCGT-3’ (anti-sense); RER: 5’-
TTCTCAGTTCACTCCCCCTCAA-3’ (sense) and 5’-
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TAACGCTTCCCAATTTCATCCA-3’ (anti-sense); angiotensinogen: 5’-
CTGCAAGGATCTTATGACCTGC-3’ (sense) and 5’-
TACACAGCAAACAGGAATGGGC-3’ (anti-sense); ACE: 5’-
CCGAAATACGTGGAACTCATCAA-3’ (sense) and 5’-
CACGAGTCCCCTGCATCTACA-3’ (anti-sense); ACE2: 5’-
CATTGGAGCAAGTGTTGGATCTT-3’ (sense)  and 5’-
GAGCTAATGCATGCCATTCTCA-3’ (anti-sense); AT1: 5’-
AGGGCAGTAAAGTTTTCGTG-3’ (sense) and 5’-
CGGGCATTGTTTTGGCAGTG-3’ (anti-sense); AT2: 5’-
GGCCTGTTTGTCCTCATTGC-3’ (sense) and 5’-
CACGGGTTATCCTGTTCTTC-3’ (anti-sense); GAPDH: 5’-
CCCATCACCATCTTCCAGGAG-3’ (sense) and 5’-
GTTGTCATGGATGACCTTGGC-3’ (anti-sense). The real time PCR reaction 
took place with a final volume of 20µl containing 0.5 mM of forward and 
reverse primer, and 2µl of single strand cDNA template in 2xQuantiTect SYBR 
Green PCR Master Mix (QIAGEN Inc., Japan). With this method, 6 orders 
linearity was obtained (Figure 1). Measurement of specific mRNA was carried 
out using the LightCycler system (Roche Diagnostics Inc., Japan). Each sample 
was run and analyzed in duplicate. The quantification was absolutely performed 
using the samples of known concentration in each run. The mRNA levels were 
expressed as relative values to GAPDH mRNA.  
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 Statistical analyses were performed with the use of SPSS Version 11.0J 
(SPSS Japan, Inc., Japan). All data are expressed as mean ± standard deviation. 
Data for clinical characteristics were evaluated by ANOVA. Differences of gene 
expressions were calculated by analysis of covariance (ANCOVA) with 4 
covariance (age, SBP and serum creatinine) for all genes and additionally with 4 
covariance (age, SBP, serum creatinine and proteinuria) for ACE as ACE up-
regulation in the rat kidney with intense proteinuria was reported (18).  
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Results  
 All the results were shown in table 3.  
 
Renal tissue REN mRNA of non-diabetic and diabetic subjects  
 REN expression was measured at 10-3 order to GAPDH expression. No 
difference was observed between the expression levels of non-diabetic subjects 
(0.89±2.12) and diabetics (0.60±0.56) (p=0.85).  
 
Renal tissue RER mRNA of non-diabetic and diabetic subjects  
 RER expression was measured at 10-3 order to GAPDH expression. No 
difference was observed between the expression levels of non-diabetic subjects 
(2.32±2.53) and diabetics (2.07±2.42) (p=0.49).  
 
Renal tissue AGT mRNA of non-diabetic and diabetic subjects  
 AGT expression was measured at 10-2 order to GAPDH expression. AGT 
expression of non-diabetic subjects (6.00±10.7) tended to higher than that of 
diabetics (2.82±2.57) with no statistical significance (p=0.27).  
 
Renal tissue ACE mRNA of non-diabetic and diabetic subjects  
 ACE expression was measured at 10-3 order to GAPDH expression. A 
significant difference was observed between ACE expression of non-diabetic 
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subjects (2.66±5.44) and diabetics (8.98±14.7) (p=0.026).  
 
Renal tissue ACE2 mRNA of non-diabetic and diabetic subjects  
 ACE2 expression was measured at 10-2 order to GAPDH expression.  
No difference was observed between the expression levels of non-diabetic 
subjects (1.94±2.83) and diabetics (2.99±2.36) (p=0.75).  
 
Renal tissue AT1 mRNA of non-diabetic and diabetic subjects  
  AT1 expression was measured at 10-2 order to GAPDH expression. AT1 
expression of non-diabetic subjects (3.54±4.03) tended to be higher than that of 
diabetics (2.50±2.11) with no statistical significance (p=0.08).  
 
Renal tissue AT2 mRNA of non-diabetic and diabetic subjects  
  AT2 expression was measured at 10-4 order to GAPDH expression. No 
difference was observed between the expression levels of non-diabetic subjects 
(2.75±4.12) and diabetics (2.50±3.42) (p=0.34).  
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Discussion  
 The results of the study suggest the up-regulation of the ACE gene in renal 
tissue of human diabetic nephropathy. For animal models a considerable number 
of data have been accumulated, especially for the streptozotosin (STZ) DM 
model. First, renal tissue angiotensin II (Ang II) concentration has been 
variously reported to be increased (19; 20), to be comparable (21) and to be 
decreased (22) compared to non-diabetic kidney. About the gene expressions of 
RAS in animal model kidney, renin expression has been reported to be increased 
at the beginning of the disease (19; 23; 24) but decreased at the late stage (20; 
23). Renal tissue AGT expression has been reported to be comparable (20; 23; 
25). Renal tissue ACE has been reported to be comparable (20; 23; 25) and to be 
decreased (26). Renal tissue ACE2 has been reported to be decreased (26). 
About receptors, it was reported that nonglycosylated AT1 receptor protein 
expression was increased in isolated glomeruli in STZ diabetic rats with no 
change in mRNA (27), while reduced expression of the AT1 receptor in diabetic 
spontaneously hypertensive rats and no such reduction in AT1 expression were 
observed in diabetic Wistar Kyoto rats (28). Since STZ diabetic animal is a 
model of insulin dependent diabetes mellitus, it is possible that the expression of 
genes differ from that of non-insulin dependent diabetes mellitus.  
 Compared to animal data, only a small number of studies have been 
conducted about the expression of renal tissue RAS on human specimens. At 
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first, elevated angiotensin II immunohistostaining was observed in tubular and 
infiltrating cells in diabetic human kidney (29). About ACE, the immunostain 
was elevated in tubular cells and appeared in interstitial cells (29). Another 
immunohistochemical study indicated that ACE staining was significantly 
enhanced in glomeruli in diabetic patients (30). The former study also reported a 
down-regulation of AT1 and up-regulation of AT2 receptors (29). These 
assessments were based on non- or semi-quantitative histochemical methods 
making precise comparisons difficult. Only one quantitative assay was made for 
AT1 expression with competitive RT-PCR method and the authors reported that 
AT1 receptor mRNA levels were significantly lower in 8 samples from patients 
with diabetic nephropathy (31).  
 As described above, systematic quantitative assessment of gene expression 
of RAS in human diabetic nephropathy has not been performed. Therefore, we 
examined this issue for the first time, and revealed the up-regulation of the ACE 
gene in renal tissue of human diabetic nephropathy among the classical and new 
major components of RAS. The previous reports of semi-quantitative 
immunohistological study on ACE were in good accordance with our study (29; 
30). Before concluding the diabetes-specific up-regulation of ACE, we should 
well exclude the effect of proteinuria in our set as ACE up-regulation in the rat 
kidney with intense proteinuria was reported (18). First, no correlation was 
found between amount of proteinuria and the ACE expression (n=74, p=0.91, 
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r=0.01). Prevalence of the subjects with nephrotic range proteinuria was not 
different between two groups (10/66 in non-diabetics and 2/8 in diabetics, 
p=0.48, χ2=0.51). At last, the difference of ACE gene expressions was calculated 
by ANCOVA with 4 covariance (age, SBP, serum creatinine and proteinuria). 
And a significant difference was confirmed between ACE expressions (p=0.028).  
 Thus, as the effects or biases of age, blood pressure, sodium intake, renal 
function and proteinuria were almost excluded, the explanation for mechanism 
of the up-regulation is unknown. Remained one possibility is the effect of 
hyperglycemia, itself. A tendency to correlation was found between HbA1c and 
the ACE expression among diabetics (n=8, p=0.24, r=0.47) and a significant 
correlation was observed among subjects including limited number of non-
diabetics (n=29, p=0.03, r=0.41). A glucose response element has been located 
on AGT gene promoter (32) but no similar element has been recognized on ACE 
gene so far. Accordingly, it is not sure the effect of hyperglycemia on renal ACE 
expression might be direct or indirect.  
 Thus, these results indicate the up-regulation of the ACE gene in renal 
tissue of human diabetic nephropathy i.e. that in spite of the hypo-reninemic 
state of the circulatory system, tissue RAS is activated. Accordingly ACEI and 
ARB might counteract this activation thereby contributing to the favorable 
effects described in large-scale prospective studies (5-11). Alternatively, in the 
view of personal oriented medicine, our assessment might provide a new 
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therapeutic approach based on renal tissue gene expression on renal diseases.  
 In summary, the gene expression of RAS i.e., renin, renin receptor, AGT, 
ACE, ACE2, AT1 and AT2 was assayed with a very small quantity of human 
renal tissues of non-diabetic and diabetic subjects by quantitative methods. The 
results suggest that renal tissue RAS might be activated in the respect that ACE 
gene expression is up-regulated in spite of a tendency to low renin expression in 
type 2 diabetic nephropathy. Further investigations including assessment of 
disease stage and severity might provide further insights into the roles of RAS in 
human diabetic nephropathy.  
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Figure 1. Measurement of renal mRNA by real-time PCR method. One example 
for measurement of renal mRNA by using the LightCycler system is 
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Table 1. Clinical characteristics of subjects at renal biopsy 
Characteristics Non diabetic Diabetic 
Number 66 8 
Gender (Male/Female) 29/37 6/2 
Age (years) 35.4±18.4 61.0±13.1* 
SBP (mmHg) 118±20 153±24* 
DBP (mmHg) 70±14 82±10 
Proteinuria (g/day)  1.36±3.56 2.52±3.22 
u-Na (mEq/gCr) 130.7±79 124.1±55.9 
s-Cr (mg/dl) 0.8±0.5 1.5±0.5* 
Ccr (ml/min) 101±54 82±52 
PRA (ng/ml/hr) 2.2±2.4 0.8±1.2 
PAC (pg/ml) 116.1±58.6 96.4±61.5 
SBP: systolic blood pressure, DBP: diastolic blood pressure, u-Na: urinary sodium, s-Cr: serum creatinine 
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Table 2. Clinical characteristics of diabetic subjects at renal biopsy 










1 F 70 type 2  7 glibenclamide 7.3 nodular 
2 M 67 type 2 23 glibenclamide  8.2 nodular 
3 F 74 type 2 19 insulin 5.1 nodular 
4 M 32 type 2  6 - 8.7 nodular 
5 M 64 type 2 26 insulin 7.2 nodular 
6 M 59 type 2 25 glibenclamide 7.4 nodular 
7 M 61 type 2  6 insulin 4.0 nodular 
8 M 55 type 2  2 - 6.3 diffuse 
DM: diabetes mellitus, HbA1c: glycosylated hemoglobin A1c, F: female; M: male, -:diet therapy only 
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Table 3. Renal tissue mRNA levels of RAS 
Gene Non diabetic Diabetic 
REN (10-3) 0.89±2.12 0.60±0.56 
RER (10-3) 2.32±2.53 2.07±2.42 
AGT (10-2) 6.00±10.7 2.82±2.57 
ACE (10-3) 2.66±5.44 8.98±14.7* 
ACE2 (10-2) 1.94±2.83 2.99±2.36 
AT1 (10-2) 3.54±4.03 2.50±2.11 
AT2 (10-4) 2.75±4.12 2.50±3.42 
Values are expressed as means ± S.D. REN: renin, RER: renin receptor, AGT: angiotensinogen, ACE: 
angiotensin converting enzyme, ACE2: angiotensin converting enzyme 2, AT1: angiotensin II type 1 receptor, 
AT2: angiotensin II type 2 receptor. *p<0.05  
 
 
